Dragonfly Therapeutics: Nicolai Wagtmann
Nicolai Wagtmann has joined Dragonfly Therapeutics as its new chief scientific officer.
Wagtmann was previously chief scientific officer at Innate Pharma, where he managed the research and development of Natural Killer (NK) cell-based therapeutic antibodies for the treatment of cancer.
At Dragonfly, Wagtmann will use the firm’s Trinket technology platform to lead the development and commercialisation of NK cell-based immunotherapies.
“He’s a gifted scientist who brings Dragonfly extraordinary depth of experience in NK cell-based therapies, a talent for leading teams through the development of breakthrough immunotherapies and a rich background of breakthrough immunotherapies and a rich background in collaborating effectively with world leading pharmaceutical companies,” said CEO Bill Haney.
Wagtmann worked at Novo Nordisk for 14 years, where he developed a portfolio of therapeutic antibodies for the treatment of cancer and inflammatory diseases, and has held positions at the Centre of Immunology in France and the National Institutes of Health, US.
He received his PhD in immunology from the University of Copenhagen.
